Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

With the advancement in magnetic resonance imaging (MRI) technology, traditional single T
1 or T 2 contrast agents struggle to meet the demend for accuracy imaging. In comparison …

Simple Summary PD-L1 plays a crucial role in the immune responses against cancer. Only
around 30% of cancer patients respond to an anti-PD-L1 immune checkpoint inhibitor …

Immune checkpoint inhibitor (ICI) therapy has emerged as a major treatment option for a
variety of cancers. Among the immune checkpoints addressed, the programmed death …

Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1
(PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to …

Abstract Purpose PD-L1 PET imaging allows for the whole body measuring its expression
across primary and metastatic tumors and visualizing its spatiotemporal dynamics before …

Purpose While TIGIT has been propelled as a next-generation target in cancer
immunotherapy, anti-TIGIT therapy seems to be promising for a fraction of patients in clinical …

The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology.
These monoclonal antibody-based therapies allow the immune system to recognize and …

Small molecules offer some advantages for developing positron emission tomography (PET)
tracers and are therefore a promising approach for imaging and therapy monitoring of …

Purpose: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients.
Tumor drug exposure measurements can provide vital insights into mechanisms involved in …